Olanzapine/fluoxetine combination for treatment-resistant depression: efficacy and clinical utility (Q37256691)

19 August 2017

1 reference

title

Olanzapine/fluoxetine combination for treatment-resistant depression: efficacy and clinical utility (English)

1 reference

treatment-resistant depression

19 August 2017

main subject

1 reference

1 reference

19 August 2017

Seetal Dodd

1 reference

19 August 2017

publication date

1 September 2008

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

19 August 2017

published in

1 reference

19 August 2017

1 reference

19 August 2017

1 reference

19 August 2017

page(s)

1299-1306

1 reference

Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1299

To combine or not to combine? A literature review of antidepressant combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1299

Augmentation strategies in patients with refractory depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1299

Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1299

New developments in psychosocial interventions for adults with unipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1299

A novel augmentation strategy for treating resistant major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1299

Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1299

Efficacy and tolerability of adjunctive ziprasidone in treatment-resistant depression: a randomized, open-label, pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1299

Influence of fluoxetine on olanzapine pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1299

Olanzapine. Pharmacokinetic and pharmacodynamic profile.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1299

Pharmacokinetics of selective serotonin reuptake inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1299

Fluoxetine metabolism and pharmacological interactions: the role of cytochrome p450

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1299

Radioreceptor binding profile of the atypical antipsychotic olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1299

Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin, alpha 1-adrenergic and muscarinic receptors in vivo in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1299

Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1299

Augmentation by citalopram of risperidone-induced monoamine release in rat prefrontal cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1299

Antipsychotic and antidepressive effects of second generation antipsychotics: two different pharmacological mechanisms?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1299

N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1299

A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1299

Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1299

Effects of olanzapine alone and olanzapine/fluoxetine combination on health-related quality of life in patients with bipolar depression: secondary analyses of a double-blind, placebo-controlled, randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1299

A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1299

A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1299

History of illness prior to a diagnosis of bipolar disorder or schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1299

Selective serotonin reuptake inhibitor discontinuation: side effects and other factors that influence medication adherence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1299

Discontinuation of use and switching of antidepressants: influence of patient-physician communication

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1299

Allostatic load in bipolar disorder: implications for pathophysiology and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1299

Glutathione: a novel treatment target in psychiatry

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1299

Leptin in depressed women: cross-sectional and longitudinal data from an epidemiologic study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1299

Dopamine dysregulation syndrome: implications for a dopamine hypothesis of bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1299

A 24-Week Open-Label Extension Study of Olanzapine-Fluoxetine Combination and Olanzapine Monotherapy in the Treatment of Bipolar Depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1299

10.1586/14737175.8.9.1299

21 January 2018

Identifiers

DOI

1 reference

19 August 2017

1 reference